INTRODUCTION AND OBJECTIVES: The aim of this study was to assess the results of kidney transplant (KT) in patients with bladder augmentation (BA).
METHODS: Between 1988 and 2015, 64 patients with BA (3 after KT) underwent kidney transplantation, due to significant lower urinary tract dysfunction. There were 40 males and 24 females. Ten second and 1 third KT were performed, comprising 75 KT in 64 patients. 44 were from living donor and 31 from deceased donor. Mean age at first KT was 22.54AE15.09 (3-64) years and mean age at first bladder augmentation was 18.31 AE 13.83 (2-64) years. The etiology of bladder dysfunction was neurogenic bladder due to spina bifida (23 patients), posterior urethral valve (12 patients), vesico-urethral reflux (6 patients), tuberculosis (8 patients) and other causes (14 patients). The bowel segments used in the augmentation included ileum in 45(70.3%) patients, ileocecal in 3(4.7%) patients and sigmoid in 4(6.3%) patients. The ureter was used in 12 (18.8%) patients. Redo BA was performed in 4 patients (1 ureterocistoplasty and 3 ileocistoplasty), all after ureterocistoplasty. In 2 patients, it was performed before the first kidney transplant.
RESULTS: Mean follow-up after first BA was 172.47 AE112,07 (11-522) months. Overall patient survival was 77.6% and actuarial graft survival at 1,2,5,7,9 and 10 years was 92%, 87.6%, 81.2%, 67.8%, 65.7% and 53.9%, respectively. Surgical complications included 1 vesicocutaneous fistula and 1 stenosis of ureteral reimplant. 51(79.7%) patients were in clean intermittent catheterization. Symptomatic or febrile urinary tract infections (UTI) occurred at least 1 episode in 79.3% of patients. Ten (62.5%) patients died of unrelated cause and 6 (37.5%) patients died due to related causes. The main cause of graft loss was chronic allograft nephropaty in 21 (77.7%) patients.
CONCLUSIONS: Augmentation cystoplasty is a safe and effective treatment for lower urinary dysfunction. Patients must be followed up closely with special attention to UTIs. Survival graft after 10 years seems to similar to regular KT recipients.
Source of Funding: None

PD38-12 THE EFFECT OF RADIOTHERAPY ON THE OUTCOME OF THE REPAIR OF URORECTAL FISTULAE
Stella Ivaz*, Simon Bugeja, Stacey Frost, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom INTRODUCTION AND OBJECTIVES: Urorectal fistulation is an uncommon consequence of a number of problems but particularly after the treatment of prostate or rectal cancer. Where there is little doubt that post-surgical fistulae can be repaired with satisfactory results, the impact of radiotherapy on the outcome of fistula repair is controversial. Herein we review our experience.
METHODS: We have repaired 127 urorectal fistulae in the last 10 years with a minimum of one year of follow-up. 24 patients have died or have been lost to follow-up leaving 41 patients who had an abdomino-perineal repair and 62 patients who had a transperineal repair -103 patients in all. Of the 41 patients having an abdominoperineal repair, 37 (90%) had had radiotherapy, or the combination of radiotherapy and surgery. Only 4 (10%) patients had a surgical cause of their fistula (NB these patients do not include patients with vesico-colic fistulae or other intra-abdominal fistulae). In the transperineal group 18 had had previous radiotherapy (29%) and the remaining 44 were purely post-surgical fistulae (71%). The principle implication for an abdominoperineal repair is to deal with sepsis in the pre-sacral space or to deal with radiotherapy problems affecting the bladder or otherwise for omental wrapping of any repair. RESULTS: After a tansperineal repair there were 5 failures in each of the two groups. All 10 failures underwent an abdomino-perineal repair subsequently with a satisfactory outcome in 4 out of 5 in each group. The overall success rate of transperineal repair, therefore, is in excess of 95%. After abdomino-perineal repair the success rate in both groups was in excess of 90% in both the surgical and the irradiation group.
CONCLUSIONS: 91% of patients with post-surgical fistulae can be treated by transperineal surgery with a 98% success rate. Only 31% of post-irradiation patients can be treated transperineally. The other 69% will require an abdomino-perineal repair and both approaches are only suitable in carefully selected patients, although the results are satisfactory in 95%. Although the overall success rate is satisfactory, the postoperative morbidity of post-irradiation patients undergoing abdomino-perineal surgery is high (62%), the recovery is protracted and the return to functional normality prolonged. INTRODUCTION AND OBJECTIVES: The potential need for clean intermittent catheterization (CIC) is known to increase in overactive bladder (OAB) patients (pts) after onabotulinumtoxinA (onabotA) treatment. We determined the risk of CIC, and efficacy and quality of life (QOL) outcomes after treatment with onabotA in different age groups in a post hoc analysis of a large cohort of OAB pts.
Source of
METHODS: Data from two onabotA randomized, placebocontrolled phase 3 trials and a post-marketing study were pooled for analysis (N¼1177). Pts treated with onabotA 100U in treatment 1 and placebo pts who received open-label onabotA in treatment 2 were grouped by age: <40 (n¼90), 40-49 (n¼156), 50-59 (n¼263), 60-69 (n¼343) and !70 (n¼325) years. Assessments at week 12 after treatment were: incidence and duration of CIC, mean and % change from baseline (BL) in urinary incontinence (UI) episodes, proportions of pts with !50% UI reduction, positive response (urinary symptoms 0 improved 0 / 0 greatly improved 0 ) on the treatment benefit scale (TBS), and change from BL in Kings Health Questionnaire (KHQ) Social Limitations and Role Limitations domains. Adverse events (AEs) were assessed.
RESULTS: CIC rates after onabotA treatment were lowest in the <40 group (1.1%) and increased slightly with age (3.2%, 5.3%, 5.3% and 7.2% in the 40-49, 50-59, 60-69 and !70 groups, respectively). Mean (median) CIC duration in the <40 and 40-49 groups was 3 (3) and 44 (26) days and ranged from 78 (68) to 88 (74) days in the e744 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
